Mon, Mar 2, 2015, 3:22 AM EST - U.S. Markets open in 6 hrs 8 mins


% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

  • akos103 akos103 Dec 1, 2011 6:41 PM Flag

    Jefferies update on OPTR today

    Jefferies maintains its Buy rating and $17 price target on Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) as it believes current valuation is attractive.

    Jefferies notes, “At its Investor and Analyst Reception on Dec 5, we expect OPTR to highlight Dificid's potential in high-risk CDAD population, its value proposition to payers, and insight into 4Q11 sales. Despite recent volatility in share price due to potential financing overhang, increased SG&A, and fluctuating IMS data, at EV of ~$370M, we believe the Street's cautious expectations for Dificid pose significant upside for OPTR shares.”

    OPTR closed at $10.74 per share on Wednesday.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
12.780.0000(0.00%)Oct 23 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.